Closed · opens tomorrow 9:30 AM ET
The Marked Chart Wire · Health
Lung Cancer
Updated findings from a study on first-line non-small cell lung cancer showed lasting benefits when pairing Merck's KEYTRUDA with Eli Lilly's olomorasib.
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
Cancer Vaccine
The two companies disclosed late-stage clinical findings for their mRNA therapy, intismeran autogene, after an information leak occurred.
Cancer Vaccines
Merck and Moderna said their personalized cancer vaccine cut the risk of melanoma recurrence or death by 42 percent in a Phase III trial. The combination showed a favorable survival trend with no new safety signals.
Moderna
Moderna stock fell about 25 percent after Phase III melanoma vaccine results reportedly leaked online. The data showed a 42 percent reduction in recurrence or death risk, a weaker result than earlier trials.
Pumitamig
BioNTech and Bristol Myers Squibb released Phase 2 data showing a 36.7 percent objective response rate for pumitamig combined with docetaxel in advanced non-small cell lung cancer.
CRISPR Therapeutics
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.